Monoclonal antibody pairs against SARS-CoV-2 for rapid antigen test development.

ABSTRACT:

Background

The focus on laboratory-based diagnosis of coronavirus disease 2019 (COVID-19) warrants alternative public health tools such as rapid antigen tests. While there are a number of commercially available antigen tests to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), all cross-react with the genetically similar SARS-CoV-1 or require an instrument for results interpretation.

Methodology/principal findings

We developed and validated rapid antigen tests that use pairs of murine-derived monoclonal antibodies (mAbs), along with gold nanoparticles, to detect SARS-CoV-2 with or without cross-reaction to SARS-CoV-1 and other coronaviruses. In this development, we demonstrate a robust antibody screening methodology for the selection of mAb pairs that can

SUBMITTER: Salcedo N 

PROVIDER: S-EPMC9004783 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature